RNA Avidity Biosciences
- 25.580
- -0.220-0.85%
- 25.530
- -0.050-0.20%
Avidity Biosciences News
Edgewise Gets EU Orphan Drug Status for Muscular Dystrophy Drug
Avidity Biosciences(RNA.US) Director Sells US$114.12K in Common Stock
$Avidity Biosciences(RNA.US)$ Director LEVIN ARTHUR A sold 5,000 shares of common stock on Apr 19, 2024 at an average price of $22.8246 for a total value of $114.12K.Source: Announcement What is state
Express News | Avidity Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
FYBR, BCRX and SABR Are Among After Hour Movers
Express News | Needham Reiterates Buy on Avidity Biosciences, Maintains $35 Price Target
Analysts Offer Insights on Healthcare Companies: Carisma Therapeutics (CARM), Avidity Biosciences (RNA) and Vera Therapeutics (VERA)
Avidity Biosciences Insider Sold Shares Worth $542,214, According to a Recent SEC Filing
Arthur A Levin, Director, on April 03, 2024, sold 20,000 shares in Avidity Biosciences (RNA) for $542,214. Following the Form 4 filing with the SEC, Levin has control over a total of 268,702 shares of
Insider Sell: Avidity Biosciences Inc (RNA) President and CEO Sarah Boyce Sells 28,000 Shares
Avidity Biosciences(RNA.US) Director Sells US$542.21K in Common Stock
$Avidity Biosciences(RNA.US)$ Director LEVIN ARTHUR A sold 20,000 shares of Common Stock on Apr 3, 2024 at an average price of $27.1107 for a total value of $542.21K.Source: Announcement What is state
Avidity Biosciences(RNA.US) Officer Sells US$734.92K in Common Stock
$Avidity Biosciences(RNA.US)$ Officer Boyce Sarah sold 28,000 shares of Common Stock on Apr 2, 2024 at an average price of $26.2471 for a total value of $734.92K.Source: Announcement What is statement
Form 144 | Avidity Biosciences(RNA.US) Director Proposes to Sell 537.4K in Common Stocks
SEC FILLINGS DISCLOSED/ Apr 3, $Avidity Biosciences(RNA.US)$ Director BUTLER-LEVIN REVOCABLE TRUST U/ADTD 05/27/2003 intends to sell 20,000 shares of its common stock on Apr 3, with a total market val
Express News | Avidity Biosciences Filed Prospectus For Proposed Resale Or Other Disposition By Selling Securityholders Of Up To 15.2M Shares Of Common Stock; Prospectus For Up To 9M Shares Issuable Upon Exercise Of Pre-funded Warrants
Avidity Biosciences Files to Sell 24.26M Common Shares for Holders
Avidity Biosciences to Participate in Upcoming Investor Conferences
SAN DIEGO, March 27, 2024 /PRNewswire/ -- Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide
Avidity Biosciences(RNA.US) Director Sells US$119.85K in Common Stocks
$Avidity Biosciences(RNA.US)$ Director LEVIN ARTHUR A sold 5,000 shares of Common Stocks on Mar 19, 2024 at an average price of $23.9695 for a total value of $119.85K.Source: Announcement What is stat
Avidity Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
SAN DIEGO, March 21, 2024 /PRNewswire/ -- Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide
Insider Sell: CFO Michael Maclean Sells 40,000 Shares of Avidity Biosciences Inc (RNA)
Avidity Biosciences(RNA.US) Officer Sells US$980.76K in Common Stocks
$Avidity Biosciences(RNA.US)$ Officer MacLean Michael F sold 40,000 shares of Common Stocks on Mar 13, 2024 at an average price of $24.519 for a total value of $980.76K.Source: Announcement What is st
Neuromuscular Focused-Avidity Biosciences Has 'Complete Package' - Analyst Predicts Stellar 142% Stock Surge
Cantor Fitzgerald has initiated coverage on Avidity Biosciences Inc (NASDAQ:RNA), noting the company has the complete package, including a strong management team, a proven platform, a robust pipeline,
Avidity Biosciences Initiated at Overweight by Cantor Fitzgerald
Avidity Biosciences Initiated at Overweight by Cantor Fitzgerald
Analysis
Price Target
No Data
